PROTEOMICS CORE

蛋白质组学核心

• 批准号: 7777677
• 负责人: ROBERT REID TOWNSEND
• 金额: $ 9.21万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7777677
• 关键词: Automobile Driving; Bioinformatics; Biology; Cancer Center; Capital; Clinical; Clinical Data; Complex; Computer software; Data; Diagnosis; Discipline; Disease; Foundations; Gastroenterology; Genomics; Goals; Hepatology; Human; Inflammatory Bowel Diseases; Laboratories; Mass Spectrum Analysis; Methods; National Cancer Institute; Patients; Peptides; Price; Process; Protein Analysis; Proteomics; Qualifying; Reagent; Research Personnel; Resources; Sampling; Scientist; Services; Speed; Technology; Tissues; United States National Institutes of Health; Wages; clinical practice; cost; cost effectiveness; data acquisition; data integration; design; discount; functional genomics; member; metabolomics; novel; prevent; ranpirnase; research study; sound; transcriptomics

Proteomics, as one of the evolving disciplines of the "omics" cascade (genomics, transcriptomics, proteomics and metabolomics) is projected to have a profound impact on the clinical practice of gastroenterology and hepatology in the coming decades (Lazaridis et al., 2005). Within the past five years, the advances in proteomics have been hallmarked by orders of magnitude increases in speed and sensitivity of data acquisition that is driving bioinformatics efforts for data interpretation and integration into the "omics" pipeline. The "data gathering" technologies for proteomics now have a firm, quantitative foundation (Feng et al., 2008). The integration of all "omics" data from the same high quality human samples is a fundamental step for the application of high-dimensional biology to preventing, diagnosing and treating Gl disorders, and is one of the imminent challenges. As discussed below under 'D. Bioinformatics and Data Integration' the assembly of proteomics data with other 'omics' data and clinical information is a major goal of the DDRCC Proteomics Core. Since the last competitive renewal, the Proteomics Core Laboratory has evolved to incorporate the most advanced technologies and software into novel, comprehensive workflows for DDRCC investigators, as detailed below. With the support of the CTSA, the Core has added staff scientists to provide DDRCC investigators the expertise and assistance to design and interpret statistically sound and cost-effective complex clinical proteomics experiments. The Core has pioneered new methods of sample processing and analysis such that proteomics and functional genomics data can be generated from the same samples that have been procured from tissues of patients with inflammatory bowel diseases (see Preliminary Results and Rader etal., 2008). The cost effectiveness of the Proteomics Core extends to the capital-intense requirements of proteomics analyses. The DDRCC resources are insufficient to support an independent unit. With increasing capacity demands for the analysis of clinical samples, the Proteomics Core has initiated and supervises an intramural mass spectrometry consortium that provides 24/7 advanced mass spectrometric analysis of proteins, peptides and metabolites in clinical samples (see Figure 17). The Proteomics Core serves as a central institutional core and is also supported by the National Institutes of Health, National Centerfor Research Resources (UL1-RR024992 (Kenneth Polonsky, Pl)'and P4r-RR000954 (Michael Gix)ss, PI), National Cancer Institute (P30 CA91842, Tim Eberlein, PI), the W. M. Keck Foundation, the Siteman Cancer Center, and other institutional resources. By subscribing to this central facility and supporting the salaries of the highly qualified staff required to carry out proteomics experiments, the DDRCC can offer its members services at a discounted price that covers only the price of supplies and reagents.

蛋白质组学，作为“组学”级联（基因组学，转录组学， 蛋白质组学和代谢组学）预计将对临床实践产生深远的影响， 胃肠病学和肝病学在未来几十年中的发展（Lazarloveet al.，2005年）。过去五年， 蛋白质组学的进步已经以蛋白质组学的速度和灵敏度的数量级增加为标志。 数据采集推动了生物信息学的数据解释和整合到“组学”中 渠道.蛋白质组学的“数据收集”技术现在有了一个坚实的定量基础（Feng et 例如，2008年）。从相同的高质量人类样本中整合所有“组学”数据是一个基本步骤 用于应用高维生物学来预防、诊断和治疗GI疾病，并且是一种 迫在眉睫的挑战。如下面在D.生物信息学与数据集成 蛋白质组学数据与其他“组学”数据和临床信息是DDRCC蛋白质组学的主要目标 核心 自上次竞争性更新以来，蛋白质组学核心实验室已经发展到将 最先进的技术和软件，为DDRCC调查人员提供新颖、全面的工作流程， 详细如下。在CTSA的支持下，核心增加了科学家，以提供DDRCC 调查人员的专业知识和协助，以设计和解释统计健全和成本效益复杂 临床蛋白质组学实验核心开创了样品处理和分析的新方法 使得蛋白质组学和功能基因组学数据可以从已经 从患有炎性肠病的患者的组织中获得（参见Preliminary Results和Rader埃塔尔， 2008年）。 蛋白质组学核心的成本效益延伸到资本密集型的要求， 蛋白质组学分析。解除武装、复员和重返社会协调中心的资源不足以支持一个独立的单位。随着增加 为了满足临床样本分析的能力需求，蛋白质组学核心已经发起并监督了一项 内部质谱联盟，提供24/7先进的质谱分析， 临床样品中的蛋白质、肽和代谢物（参见图17）。蛋白质组学核心作为一个 中央机构的核心，也是由美国国立卫生研究院，国家中心的支持， 研究资源（UL 1-RR 024992（Kenneth Polonsky，PI）和P4 r-RR 000954（Michael Gix）ss，PI）， 美国国家癌症研究所（P30 CA 91842，蒂姆Eberlein，PI），W。M.凯克基金会，Siteman癌症 中心和其他机构资源。通过订阅这一中央设施和支持 开展蛋白质组学实验所需的高素质工作人员，DDRCC可以为其成员提供 以仅包括供应品和试剂价格的折扣价格提供服务。